Sanofi backs $90M financing for I&I biologic developer

Title

Sanofi Leads $90M Series C for Attovia Therapeutics, Advancing Next-Generation I&I Biologics

Keywords

• Sanofi
• Attovia Therapeutics
• Series C financing
• Immunology and inflammation (I&I)
• Biologics
• Antibody engineering
• Attobody platform
• Chronic pruritus
• Atopic dermatitis
• Bispecific antibodies
• Venture capital

Key Facts

- $90 Million Series C Financing:
Attovia Therapeutics raised $90 million in an oversubscribed Series C round, supported by Sanofi Ventures and other major investors, bringing its total funding to $255 million over three years12.

- Lead Assets: The financing will fund clinical proof-of-concept studies for two main drug candidates:

* - ATTO-1310:*
A subcutaneous, half-life extended anti-IL-31 biotherapeutic targeting pruritic conditions, including chronic pruritus of unknown origin.

* - ATTO-3712:*
A first-in-class bispecific biologic targeting both IL-3 and IL-31, aimed at treating atopic dermatitis and other inflammatory disorders1.

- Innovative Attobody™ Platform: Attovia’s pipeline is built on its proprietary Attobody™ technology, which engineers “biparatopic” nanobodies that bind two epitopes, offering:

• Enhanced potency and target engagement
• Modular, “Lego-like” design for rapid development of bi- and multi-specific antibodies
• Extended half-life and infrequent dosing schedules, attracting significant interest for immune-mediated indications like inflammatory bowel disease1.

- Pipeline Expansion:
Additional assets in development include multi-specific drug ATTO-004 for IBD, and two undisclosed early-stage multispecific programs (ATTO-005 and ATTO-006)1.

- Investor Consortium:
Deep Track Capital led the Series C, joined by new investors (Vida Ventures, Mirae Asset) and existing backers (Frazier Life Sciences, venBio, Goldman Sachs Alternatives, Cormorant Asset Management, and more)1.

- Strategic Importance:
The investment reflects Sanofi's continued commitment to expand its immunology and inflammation franchise and support innovative antibody platforms for unmet medical needs in autoimmune and inflammatory diseases101.

- Financial Outlook:
The funds provide Attovia with several years of operational runway as it advances multiple clinical and preclinical programs1.

Sources:

1. https://www.genengnews.com/topics/drug-discovery/attovia-building-immune-mediated-disease-pipeline-with-90m-series-c/

2. https://www.fiercebiotech.com/biotech/fierce-biotech-fundraising-tracker-25

10. https://www.biospace.com/business/sanofi-commits-1-9b-for-dren-bios-bispecific-antibody-for-autoimmune-disease